TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial
Shares of TransCode Therapeutics Inc jumped nearly 19% Thursday following a U.S. regulatory update related to its lead drug program. The stock traded around $10.23, swinging between $9.08 and $12.30, as volume surged to about 11.5 million shares compared to roughly 8,500 the previous day.
TechStock² Updates
![Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-28-0051-480x384.jpg "Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]")
